Growth Factor News and Research

RSS

Angiogenesis : Blocking tumor growth and treating infarction - a new target

Our tissues are able to form new blood vessels throughout life. This mechanism, which is called angiogenesis, is essential notably in the case of myocardial infarction, stroke and limb ischemia. The very same mechanism, however, keeps tumors supplied with nutrients and oxygen thus enabling them to continue growing.

27 Apr 2005

Gene therapy for Alzheimer's disease shows promise

In the first clinical trial of gene therapy for Alzheimer's disease researchers have produced preliminary evidence that gene therapy may slow the decline in mental functioning associated with Alzheimer's disease.

25 Apr 2005

Substantially more effective therapy than current treatments for Alzheimer's disease

PET scans and cognitive tests have suggested that Alzheimer's disease patients with genetically modified tissue inserted directly into their brains show a reduction in the rate of cognitive decline and increased metabolic activity in the brain, according to a study published in the April 24, 2005 online issue of the journal Nature Medicine by researchers at the University of California, San Diego (UCSD) School of Medicine.

25 Apr 2005

First time video capture of chemical signals that traverse human cells messaging

Researchers at UCSD and UC Irvine have captured on video for the first time chemical signals that traverse human cells in response to tiny mechanical jabs, like waves spreading from pebbles tossed into a pond. The scientists released the videos and technical details that explain how the visualization effect was created as part of a paper published in the April 21 issue of Nature.

21 Apr 2005

Breast cancer gene may play a major role in the recurrence of prostate cancer

A gene associated with breast cancer also may play a major role in the recurrence of prostate cancer, according to new research from the University of North Carolina at Chapel Hill School of Medicine and UNC Lineberger Comprehensive Cancer Center.

20 Apr 2005

Researchers find ovarian cancer patients who appear to respond better than others to gefitinib, or Iressa

Researchers at Fox Chase Cancer Center in Philadelphia have identified a subset of ovarian cancer patients who appear to respond better than others to gefitinib, or Iressa. The research was presented today at the 96th Annual Meeting of the American Association for Cancer Research in Anaheim, Calif.

20 Apr 2005

Vegetables such as broccoli and spices like red chili pepper, may provide a cancer-fighting benefit

Two new studies suggest that vegetables such as broccoli and spices like red chili pepper, may provide a cancer-fighting benefit by slowing or preventing the growth of cancerous tumor cells. The findings, being presented at the annual meeting of the American Association for Cancer Research held April 16 to 20 at the Anaheim Convention Center in Anaheim, Calif., looked at the effect of these dietary agents on cancers that have extremely poor prognoses despite advances in surgery and other therapies.

19 Apr 2005

Researchers determine structure of binding site of colon-cancer drug Erbitux and its protein target

Researchers at the University of Pennsylvania School of Medicine have determined the precise molecular details of how Erbitux, a recently approved colorectal cancer drug, binds to its target on cancer cells. Knowing this chemical configuration will lead to better drug design for this family of cancer medications.

19 Apr 2005

Chemical library aids in developing drug system for nerve damage

A researcher studying drug design for nerve damage therapies has gotten her answer to questions by following some old advice: she used the library.

12 Apr 2005

Researcher grows new insulin-secreting beta cells from pancreatic tissue

JDRF-funded researchers in Canada and Massachusetts have stimulated the birth of new insulin-secreting beta cells by treating human islets with a mixture of two naturally occurring peptides: epidermal growth factor (EGF) and gastrin.

12 Apr 2005

Gene therapy shows effect in heart patients

The first double-blind, placebo-controlled randomized trial of VEGF gene injections into the heart muscle of patients with coronary artery disease with the intention of spurring growth of new blood vessels showed significant effects on heart wall motion, although blood flow was not significantly better in treated patients, according to a new study in the April 5, 2005, issue of the Journal of the American College of Cardiology.

5 Apr 2005

Adding growth factor to baby formula could reduce necrotizing enterocolitis

Could it be that the most widespread and devastating gastrointestinal disease affecting premature babies could be conquered simply by adding a common polypeptide, epidermal growth factor (EGF), to infant formula? And if so, exactly how does it work, and why?

3 Apr 2005

Herceptin - more powerful treatment for patients with HER-2-positive breast cancer

A new use of the drug Herceptin appears to offer a much more powerful treatment advantage than expected for patients with HER-2-positive breast cancer, say researchers at The University of Texas M. D. Anderson Cancer Center.

29 Mar 2005

Discovery of gene STAT6(B) may lead to new treatments for inflammatory diseases

In a paper featured in Proceedings of the National Academy of Science (PNAS), researchers from Boston University School of Dental Medicine report the discovery of a new gene, STAT6(B), that helps regulate production of the potentially deadly tumor necrosis factor alpha (TNF-alpha) cytokine.

28 Mar 2005

Vegetarians who don't cook their food have abnormally low bone mass

Vegetarians who don't cook their food have abnormally low bone mass, usually a sign of osteoporosis and increased fracture risk. But a research team at Washington University School of Medicine in St. Louis also found that raw food vegetarians have other biological markers indicating their bones, although light in weight, may be healthy.

28 Mar 2005

Drug combo gives lung cancer patients longer life

Preliminary results from a large randomized clinical trial, sponsored by the National Cancer Institute (NCI), by a network of researchers led by the Eastern Cooperative Oncology Group. Genentech, Inc., have shown that patients with previously untreated advanced non-squamous non-small cell lung cancer who received bevacizumab (Avastin) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without bevacizumab.

15 Mar 2005

Bevacizumab (Avastin) in combination with standard chemotherapy helps advanced lung cancer sufferers

Preliminary results from a large, randomized clinical trial for patients with previously untreated advanced non-squamous, non-small cell lung cancer show that those patients who received bevacizumab (AvastinTM) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without bevacizumab.

15 Mar 2005

Tumor-targeted immune cells cure prostate cancer without causing systemic immune suppression

In a major breakthrough in cancer gene therapy, a Northwestern University researcher has endowed immune cells with the ability to specifically target metastatic prostate cancer in mice without causing the toxic immune suppression that has been associated with earlier forms of cancer gene therapy.

14 Mar 2005

Substances in the urine of pregnant women could serve as a screening/diagnostic tool for preeclampsia

Researchers at Yale School of Medicine have found that specific substances in the urine of pregnant women could serve as a screening/diagnostic tool for preeclampsia (hypertension and proteinuria during pregnancy).

7 Mar 2005

ViroLogic and AstraZeneca to conduct Iressa biomarker study

ViroLogic announced today that it had entered into an agreement with AstraZeneca to conduct a cancer biomarker study with application to Iressa, AstraZeneca's selective epidermal growth factor receptor kinase inhibitor.